Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 3/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CASP1 | P29466 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | CASP7 | P55210 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.35 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 6/20 | 0.33 |
| ▸ | BACE2 | Q9Y5Z0 | 3/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24697302 | 0.79 | CA2 (0.44) | CA9CA12BACE1CA1CA2 | |
| SCHEMBL31568291 | 0.79 | CA2 (0.44) | CA9CA12BACE1CA1CA2 | |
| Ammonia Solution, Strong SCHEMBL446104 | 0.72 | KMT2A (0.38) | CA9CA12KDM4EMAPTHSD17B10 | |
| SCHEMBL5188773 | 0.70 | CA12 (0.39) | CA9CA12KDM4EMAPTBACE1 | |
| SCHEMBL14425421 | 0.69 | CA1 (0.41) | CA9CA12KDM4EMAPTRECQL | |
| SCHEMBL31568209 | 0.68 | CA1 (0.41) | CA9CA12BACE1BACE2CA1 | |
| SCHEMBL6193575 | 0.68 | CA12 (0.40) | CA9CA12CA1CA2 | |
| SCHEMBL9243179 | 0.63 | KMT2A (0.50) | CA9CA12KDM4EGAAMAPT | |
| SCHEMBL1709872 | 0.63 | CA9 (0.44) | CA9CA12KDM4EGAAMAPT | |
| SCHEMBL2144444 | 0.62 | NPC1 (0.37) | CA9CA12CASP1CASP7NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070259891-A1 | Heterocycle-Substituted Cyclic Urea Derivatives, Preparation Thereof And Pharmaceutical Use Thereof As Kinase Inhibitors | AVENTIS PHARMA S.A. (FR) | 2007-11-08 | — | — | US | disclosed |
| US-7101868-B2 | Substituted arylamine derivatives and methods of use | AMGEN INC. (US) | 2006-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259891-A1 | Heterocycle-Substituted Cyclic Urea Derivatives, Preparation Thereof And Pharmaceutical Use Thereof As Kinase Inhibitors | CDK1, PRKAR2B, MAP3K19 | CA9 3416/4885CA12 4622/4885KDM4E 1363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.